290 related articles for article (PubMed ID: 1505075)
21. Improved antitumor activity of cis-Bis-neodecanoato-trans-R,R-1,2- diaminocyclohexaneplatinum (II) entrapped in long-circulating liposomes.
Li S; Khokhar AR; Perez-Soler R; Huang L
Oncol Res; 1995; 7(12):611-7. PubMed ID: 8704278
[TBL] [Abstract][Full Text] [Related]
22. Intraliposomal conversion of lipophilic cis-bis-carboxylato-trans-R,R-1,2-diaminocyclohexane-platinum (II) complexes into cis-bis-dichloro-trans-R,R-1,2-diaminocyclohexane-platinum (II).
Han I; Khokhar AR; Perez-Soler R
Cancer Chemother Pharmacol; 1996; 39(1-2):17-24. PubMed ID: 8995495
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic behaviour of cisplatin in peritoneal fluid after intraperitoneal administration of cisplatin-loaded microspheres.
Tamura T; Imai J; Matsukawa Y; Horikiri Y; Suzuki T; Yoshino H; Ike O
J Pharm Pharmacol; 2001 Oct; 53(10):1331-9. PubMed ID: 11697540
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and tissue distribution of iv injection of polyphase liposome-encapsulated cisplatin (KM-1) in rats.
Wang S; Mi JB; Li YZ; Chang WB; Ci YX; Zhao MZ; Zhao YK; Zhu LY; Xu G
Acta Pharmacol Sin; 2003 Jun; 24(6):589-92. PubMed ID: 12791187
[TBL] [Abstract][Full Text] [Related]
25. Improved pharmacological profile of the lipophilic antitumor dichloro-(N-dodecyl)-propanediamine-platinum(II) complex after incorporation into pegylated liposomes.
Silva H; Silva AC; Lemos FO; Monte-Neto RL; Fontes AP; Lopes MT; Frézard F
Anticancer Drugs; 2013 Feb; 24(2):131-9. PubMed ID: 23011234
[TBL] [Abstract][Full Text] [Related]
26. Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment.
Los G; Mutsaers PH; Lenglet WJ; Baldew GS; McVie JG
Cancer Chemother Pharmacol; 1990; 25(6):389-94. PubMed ID: 2311166
[TBL] [Abstract][Full Text] [Related]
27. Toxicity and efficacy studies on a series of lipid-soluble dineodecanoato(trans-R,R- and trans-S,S-1,2-diaminocyclohexane) platinum (II) complexes entrapped in liposomes.
Khokhar AR; al-Baker S; Perez-Soler R
Anticancer Drugs; 1992 Apr; 3(2):95-100. PubMed ID: 1525398
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of tetraplatin administered intraperitoneally with reduced glutathione in mice.
Kido Y; Khokhar AR; Yoshida M; Thai GW; Siddik ZH
Drug Metab Dispos; 1994; 22(2):312-7. PubMed ID: 8013287
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic and pharmacodynamic analysis of platinum after combined treatment of cisplatin and procainamide hydrochloride in mice bearing P388 leukemia.
Vannozzi MO; Ottone M; Mariggiò MA; Cafaggi S; Parodi B; Cilli M; Lindup E; Viale M
Anticancer Res; 2003; 23(2B):1509-16. PubMed ID: 12820417
[TBL] [Abstract][Full Text] [Related]
30. In vitro cytotoxicity, pharmacokinetics and ex vivo pharmacodynamics of a new platinum compound, cis-malonato [(4R,5R-4,5-bis(aminomethyl)-1,3-dioxolane-2-spiro-1'-cyclopentane] platinum (II).
Kim DK; Kim HT; Cho YB; Kim TS; Kim KH; Hong WS
Anticancer Res; 1996; 16(1):251-6. PubMed ID: 8615617
[TBL] [Abstract][Full Text] [Related]
31. Transplacental passage of Pt after treatment with the new triamine complex cis-diaminechloro-[2-(diethylamino) ethyl 4-amino-benzoate, N4]-chloride platinum (II) monohydrochloride monohydrate.
Ognio E; Chiavarina B; Caviglioli G; Lapide M; Viale M
Arch Toxicol; 2004 Oct; 78(10):584-8. PubMed ID: 15150682
[TBL] [Abstract][Full Text] [Related]
32. Use of cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II), a liposomal cisplatin analogue, in cats with oral squamous cell carcinoma.
Fox LE; Rosenthal RC; King RR; Levine PB; Vail DM; Helfand SC; MacEwen EG; Perez-Soler R; Calderwood-Mays M; Kurzman ID
Am J Vet Res; 2000 Jul; 61(7):791-5. PubMed ID: 10895902
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics and tissue distribution of cisplatin in nude mice: platinum levels and cisplatin-DNA adducts.
Johnsson A; Olsson C; Nygren O; Nilsson M; Seiving B; Cavallin-Stahl E
Cancer Chemother Pharmacol; 1995; 37(1-2):23-31. PubMed ID: 7497593
[TBL] [Abstract][Full Text] [Related]
34. A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer.
Dragovich T; Mendelson D; Kurtin S; Richardson K; Von Hoff D; Hoos A
Cancer Chemother Pharmacol; 2006 Dec; 58(6):759-64. PubMed ID: 16847673
[TBL] [Abstract][Full Text] [Related]
35. Cholephilic characteristics of a new cytostatic complex of cisplatin with glycocholate (Bamet-R2).
Macias RI; El-Mir MY; Monte MJ; Serrano MA; Garcia MJ; Marin JJ
J Control Release; 1999 Feb; 57(2):161-9. PubMed ID: 9971896
[TBL] [Abstract][Full Text] [Related]
36. Neutron activation of NDDP, a liposomal platinum antitumor agent.
MacLean DS; Khokhar AR; Perez-Soler R
Cancer Biother Radiopharm; 2000 Jun; 15(3):253-9. PubMed ID: 10941532
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics and tissue distribution of liposome-encapsulated cis-bis-N-decyl-iminodiacetato-1,2-diaminocyclohexane-platinum (II).
Lautersztain J; Perez-Soler R; Khokhar AR; Newman RA; Lopez-Berestein G
Cancer Chemother Pharmacol; 1986; 18(2):93-7. PubMed ID: 3791565
[TBL] [Abstract][Full Text] [Related]
38. Cisplatin pharmacokinetics and its nephrotoxicity in diabetic rabbits.
Najjar TA; Saad SY
Chemotherapy; 2001; 47(2):128-35. PubMed ID: 11173815
[TBL] [Abstract][Full Text] [Related]
39. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of (1R,2R-diaminocyclohexane)oxalatoplatinum(II) in comparison with cisplatin following a single intravenous injection in rabbits.
Kizu R; Higashi S; Kidani Y; Miyazaki M
Cancer Chemother Pharmacol; 1993; 31(6):475-80. PubMed ID: 8453687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
